Tests for treatment group differences in the hazards for survival, before and after the occurrence of an intermediate event

Statistics in Medicine

Volumn 24, Issue 3, 2005, Pages 359-378

  Bebchuk, Judith D ^a   Betensky, Rebecca A ^b  

^a UNIVERSITY OF MINNESOTA   (United States)

^b HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Hazard testing; Power estimation; Three state model; Time dependent stratification

Indexed keywords

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; CLINICAL PROTOCOL; CLINICAL RESEARCH; COMPUTER PROGRAM; DEATH; HAZARD ASSESSMENT; HUMAN; MATHEMATICAL COMPUTING; METHODOLOGY; PROBABILITY; PROGNOSIS; REGRESSION ANALYSIS; SCORING SYSTEM; SIMULATION; STATISTICAL MODEL; SURVIVAL;

ACQUIRED IMMUNODEFICIENCY SYNDROME; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTIVIRAL AGENTS; COMPUTER SIMULATION; DOUBLE-BLIND METHOD; HUMANS; LIKELIHOOD FUNCTIONS; MARKOV CHAINS; PNEUMOCYSTIS CARINII; PNEUMONIA, PNEUMOCYSTIS; PROPORTIONAL HAZARDS MODELS; RANDOMIZED CONTROLLED TRIALS; SURVIVAL ANALYSIS;

EID: 13644260290     PISSN: 02776715     EISSN: None     Source Type: Journal    
DOI: 10.1002/sim.2019     Document Type: Article

References (10)

1. Bebchuk JD, Betensky RA. Local likelihood analysis of survival data with censored intermediate events. Journal of the American Statistical Association 2001; 96:449-457.
2. Bebchuk JD, Betensky RA. Local likelihood based estimation and testing of latency distributions with interval censored intermediate events. Statistics in Medicine 2002; 21:3475-3491.
3. Tsiatis AA. An example of nonidentifiability in competing risks. Scandinavian Actuarial Journal 1978; 235-239.
4. Kalbfleisch JD, Prentice RL. The Statistical Analysis of Failure Time Data, Chapter 7. Wiley: New York, 1980.
5. Hardy WD, Feinberg J, Finkelstein DM, Power ME, He W, Kaczka C, Holmes M, Waskin H, Fass RJ et al. A controlled trial of trimethoprim-sulfame thoxazde or aerosolized pentamidine for secondary prophylaxis of pneumocystis carinii pneumonia in patients with the acquired immunodeficiency syndrome. AIDS Clinical Trials Group Protocol 021. New England Journal of Medicine 1992; 327:1842-1848.
6. Lagakos SW. A stochastic model for censored-survival data in the presence of an auxiliary variable. Biometrics 1976; 32 551-559.
7. Finkelstein DM, Schoenfeld DA. Analyzing survival in the presence of an auxiliary variable. Statistics in Medicine 1994; 13:1747-1754.
8. Gray RJ. A kernel method for incorporating information on disease progression in the analysis of survival. Biometrika 1994; 81:527-539.
9. Pepe MS, Fleming TR. Weighted Kaplan-Meier statistics: a class of distance tests for censored survival data. Biometrics 1989; 45:497-507.
10. Pepe MS, Fleming TR. Weighted Kaplan-Meier statistics: large sample and optimality considerations. Journal of the Royal Statistical Society, Series B, Methodological 1991; 53:341-352.